HIFs, angiogenesis, and cancer

Journal of Cellular Biochemistry

Volumn 114, Issue 5, 2013, Pages 967-974

  Yang, Yongzhi ^a   Sun, Mingjuan ^a   Wang, Lianghua ^a   Jiao, Binghua ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

angiogenesis; cancer; hypoxia inducible factor 1 (HIF 1)

Indexed keywords

10 HYDROXYGLAUCANETIN; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; AMPHOTERICIN B; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANTINEOPLASTIC AGENT; APIGENIN; AW 464; BORTEZOMIB; CAMPTOTHECIN; CAULERPIN; CHETOCIN; CHETOMIN; CRYPTOPLEURINE; CURCUMIN; ECHINOMYCIN; EZN 2968; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; LIFICIGUAT; MANASSANTIN A; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PLEUROTIN; RESVERATROL; SIBIRIQUINONE A; TRICHOSTATIN A; UNCLASSIFIED DRUG; VASCULOTROPIN; WORTMANNIN;

ANGIOGENESIS; ARTICLE; CANCER THERAPY; GENE CONTROL; HUMAN; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN STRUCTURE;

ANIMALS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 84875158140     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24438     Document Type: Article

References (76)

1. Bamias A, Dimopoulos MA,. 2003. Angiogenesis in human cancer: Implications in cancer therapy. Eur J Intern Med 14: 459-469.
2. Belozerov VE, Van Meir EG,. 2005. Hypoxia inducible factor-1: A novel target for cancer therapy. Anticancer Drugs 16: 901-909.
3. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J,. 2003. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22: 4082-4090.
4. Cai XF, Jin X, Lee D, Yang YT, Lee K, Hong YS, Lee JH, Lee JJ,. 2006. Phenan-throquinolizidine alkaloids from the roots of Boehmeria pannosa potently inhibit hypoxia-inducible factor-1 in AGS human gastric cancer cells. J Nat Prod 69: 1095-1097.
5. Carmeliet P,. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395.
6. Carrozza MJ, Utley RT, Workman JL, Cote J,. 2003. The diverse functions of histone acetyltransferase complexes. Trends Genet 19: 321-329.
7. Choi H, Chun YS, Kim SW, Kim MS, Park JW,. 2006. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: A mechanism of tumor growth inhibition. Mol Pharmacol 70: 1664-1671.
8. Coothankandaswamy V, Liu Y, Mao SC, Morgan JB, Mahdi F, Jekabsons MB, Nagle DG, Zhou YD,. 2010. The alternative medicine pawpaw and its acetogenin constituents suppress tumor angiogenesis via the HIF-1/VEGF pathway. J Nat Prod 73: 956-961.
9. Dat NT, Jin XJ, Lee JH, Lee DH, Hong YS, Lee K, Kim YH, Lee JJ,. 2007. Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1. J Nat Prod 70: 1093-1097.
10. Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH,. 2005. Apigenin inhibits VEGF and HIF-1 expression via PI3K/Akt/p70S6K1 and HDM2/p53 pathways. FASEB J 19: 342-353.
11. Folkman J,. 1990. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6.
12. Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, Frydenlund HF, Albaek C, Schrøder H, Orum H,. 2008. A RNA antagonist of hypoxia-inducible factor-1alpha. EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 7: 3598-3608.
13. Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, Lee HY,. 2005. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyl transferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 97: 1272-1286.
14. Han Y, Yang K, Proweller A, Zhou G, Jain MK, Ramirez-Bergeron DL,. 2012. Inhibition of ARNT severely compromises endothelial cell viability and function in response to moderate hypoxia. Angiogenesis 15: 409-420.
15. Hanahan D, Folkman J,. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353e64.
16. Hanahan D, Weinberg RA,. 2000. The hallmarks of cancer. Cell 100: 57-70.
17. Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, Welford RW, Elkins JM, Oldham NJ, Bhattacharya S, Gleadle JM, Ratcliffe PJ, Pugh CW, Schofield CJ,. 2002. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 277: 26351-26355.
18. Hickey MM, Simon MC,. 2006. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr Top Dev Biol 76: 217-257.
19. Höpfl G, Ogunshola O, Gassmann M,. 2004. HIFs and tumors-Causes and consequences. Am J Physiol Regul Integr Comp Physiol 286: R608-R623.
20. Hur E, Kim HH, Choi SM, Kim JH, Yim S, Kwon HJ, Choi Y, Kim DK, Lee MO, Park H,. 2002. Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol Pharmacol 62: 975-982.
21. Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM, Bible KC,. 2007. Chaetocin: A promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 109: 2579-2588.
22. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, Kim KW,. 2002. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111: 709-720.
23. Jiang BH, Liu LZ,. 2008. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 1784: 150-158.
24. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL,. 1997. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem 272: 19253-19260.
25. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK,. 2001. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12: 363-369.
26. Jones DT, Harris AL,. 2006. Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Mol Cancer Ther 5: 2193-2202.
27. Jones DT, Pugh CW, Wigfield S,. 2006. Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor alpha expression but decrease functional transcriptional activity, DNA binding, and degradation. Clin Cancer Res 12: 5384-5394.
28. Kaelin WG, Jr., 2002. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2: 673-682.
29. Kaelin WG,. 2005. Proline hydroxylation and gene expression. Annu Rev Biochem 74: 115-128.
30. Kaluz S, Kaluzová M, Stanbridge EJ,. 2006. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1a C-terminal activation domain. Mol Cell Biol 26: 5895-5907.
31. Kasper AC, Moon EJ, Hu XQ, Park Y, Wooten CM, Kim H, Yang WT, Dewhirst MW, Hong JY,. 2009. Analysis of HIF-1 inhibition by manassantin A and analogues with modified tetrahydrofuran configurations. Bioorg Med Chem Lett 19: 3783-3786.
32. Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, Fisher RJ, Shoemaker RH, Melillo G,. 2005. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 65: 9047-9055.
33. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J,. 2006. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 26: 2019-2028.
34. Koop EA, Lopes SM, Feiken E, Bluyssen HA, van der Valk M, Voest EE, Mummery CL, Moolenaar WH, Gebbink MF,. 2003. Receptor protein tyrosine phosphatase mu expression as a marker for endothelial cell heterogeneity; analysis of RPTPmu gene expression using LacZ knock-in mice. Int J Dev Biol 47: 345-354.
35. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, Semenza GL,. 2003. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63: 1138-1143.
36. Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J, Memmert K, Naegeli HU, Petersen F, Eck MJ, Bair KW, Wood AW, Livingston DM,. 2004a. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6: 33-43.
37. Kung AL, Zabludoff SD, France DS,. 2004b. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6: 33-43.
38. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL,. 2001. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004.
39. LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, Suwandi L, Hanson AD, Fogler WE, Sidor CF, Treston AM,. 2008. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol Cancer Ther 7: 1472-1482.
40. Lee YM, Kim SH, Kim HS, Jin SM, Nakajima H, Jeong KH, Kim KW,. 2003. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1a activity. Biochem Biophys Res Commun 300: 241-246.
41. Lee K, Kang JE, Park SK, Jin YL, Chung KS, Kim HM, Lee K, Kang MR, Lee MK, Song KB, Yang EG, Lee JJ, Won MS,. 2010. LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1a via upregulation of VHL in a colon cancer cell line. Biochem Pharmacol 80: 982-989.
42. Levy AP, Levy NS, Wegner S, Goldberg MA,. 1995. Transcriptional regulation of the rat vascular endothelial growth factor by hypoxia. J Biol Chem 270: 13333-13340.
43. Li SH, Shin DH, Chun YS, Lee MK, Kim MS, Park JW,. 2008. A novel mode of action of YC-1 in HIF inhibition: Stimulation of FIH-dependent p300 dissociation from HIF-1a. Mol Cancer Ther 7: 3729-3738.
44. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich JN,. 2009. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15: 501-513.
45. Liu Y, Morgan JB, Coothankandaswamy V, Liu R, Jekabsons MB, Mahdi F, Nagle DG, Zhou YD,. 2009. The Caulerpa pigment caulerpin inhibits HIF-1 activation and mitochondrial respiration. J Nat Prod 72: 2104-2109.
46. Macpherson GR, Figg WD,. 2004. Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade. Cancer Biol Ther 3: 503-504.
47. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, Cao Y, Berkenstam A, Poellinger L,. 2001. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414: 550-554.
48. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, Semenza GL,. 2005. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105: 659-669.
49. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ,. 2001. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 20: 5197-5206.
50. Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, Ohh M,. 2003. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 278: 11032-11040.
51. Metzen E, Berchner-Pfannschmidt U, Stengel P, Marxsen JH, Stolze I, Klinger M, Huang WQ, Wotzlaw C, Hellwig-Bürgel T, Jelkmann W, Acker H, Fandrey J,. 2003. Intracellular localisation of human HIF-1 alpha hydroxylases: Implications for oxygen sensing. J Cell Sci 116: 1319-1326.
52. Michel G, Minet E, Ernest I, Roland I, Durant F, Remacle J, Michiels C,. 2000. A model for the complex between the hypoxia-inducible factor-1 (HIF-1) and its consensus DNA sequence. J Biomol Struct Dyn 18: 169-179.
53. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L,. 2006. VEGF receptor signalling-In control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
54. Porter JR, Ge J, Lee J, Normant E, West K,. 2009. Ansamycin inhibitors of Hsp90: Nature's prototype for anti-chaperone therapy. Curr Top Med Chem 9: 1386-1418.
55. Qian DZ, Kachhap SK, Collis SJ, Verheul HMW, Carducci MA, Atadja P, Pili R,. 2006. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 66: 8814-8821.
56. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G,. 2004. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications. Cancer Res 64: 1475-1482.
57. Rzeski W, Walczak K, Juszczak M, Langner E, Pożarowski P, Kandefer-Szerszeń M, Pierzynowski SG,. 2012. Alpha-ketoglutarate (AKG) inhibits proliferation of colon adenocarcinoma cells in normoxic conditions. Scand J Gastroenterol 47 (5): 565-571.
58. Safran M, Kaelin WG, Jr., 2003. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 111: 779-783.
59. Semenza GL,. 2003. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
60. Seung BR, Yong JS, Myong CL, Seung-Hoon L, Boh-Ram K, Sang-Yoon P,. 2012. Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. Cell Signal 24: 131-139.
61. Shimizu K, Maruyama M, Yasui Y, Minegishi H, Ban HS, Nakamura H,. 2010. Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1a inhibitors. Bioorg Med Chem Lett 20: 1453-1456.
62. Skuli N, Liu L, Runge A, Wang T, Yuan L, Patel S, Iruela-Arispe L, Simon MC, Keith B,. 2009. Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood 114 (2): 469-477 [Epub 2009 May 13].
63. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, Ferrara N, Johnson RS,. 2004. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6: 485-495.
64. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E,. 2002. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 277: 27975-27981.
65. Verma RP, Hansch C,. 2009. Camptothecins: A SAR/QSAR study. Chem Rev 109: 213-235.
66. Wan X, Shen N, Mendoza A,. 2006. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/HIF-1alpha/VEGF signaling. Neoplasia 8: 394-401.
67. Welsh SJ, Powis G,. 2003a. Hypoxia inducible factor as a cancer drug target. Curr Cancer Drug Targets 3: 391-405.
68. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G,. 2003b. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2: 235-243.
69. Won MS, Im N, Park S, Boovanahalli SK, Jin YL, Jin XJ, Chung KS, Kang M, Lee K, Park SK, Kim HM, Kwon BM, Lee JJ, Lee K,. 2009. A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway. Biochem Biophys Res Commun 385: 16-21.
70. Xia Y, Jin YL, Kaur N, Choi Y, Lee K,. 2011. HIF-1a inhibitors: synthesis and biological evaluation of novel moracin O and P analogues. Eur J Med Chem 46: 2386-2396.
71. Yan X, Hyun-Kyung C, Kyeong L,. 2012. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 49: 24-40.
72. Yeo EJ, Ryu JH, Cho YS, Chun YS, Huang LE, Kim MS, Park JW,. 2006. Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 107: 916-923.
73. Yewalkar N, Deore V, Padgaonkar A, Manohar S, Sahu B, Kumar P, Jalota-Badhwar A, Joshi KS, Sharma S, Kumar S,. 2010. Development of novel inhibitors targeting HIF-1a towards anticancer drug discovery. Bioorg Med Chem Lett 20: 6426-6429.
74. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD,. 2005. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 4: 1465-1474.
75. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL,. 2000. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545.
76. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ,. 2000. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14: 391-396.